Human genes contain the recipes and properties of various proteins that your cells need to functional normally. Cells need the proteins to stay healthy. There are some genes and the proteins produced can impact the development of breast cancer, or its response to a particular form of therapy. You can test cancel cells from a perfect tissue sample for figuring out the abnormal and normal genes. You can also test the proteins. The context of human epidermal growth factor receptor 2 or her2 is very important here. There’s another crucial gene with the ability of playing a clinical role in the cancer treatment. The pathology test exams should have HER2 status index, which would state its role in the malaise. This gene is another name, ERBB2 gene. Deducing the influence: This genes are the makers of HER2 proteins. These proteins are the main receptors of your breast cells. Generally, HER2 receptors can control the tempo and mode of growth of a breast cell, or impact the way it repairs or divides itself. However, contemporary study shows that in almost 25-30% of breast cancers today, this gene doesn’t function properly and makes plenty of copies or replicas of it. This occurrence is called HER2 gene accentuation. All the extra genes lead to breast cells producing excess overflow of HER2 receptors or protein alongside the over expression. The main impact is that your breast cells divide and grow in an unbridled manner. Concluding the four tests: The first test is called the Immunohistochemistry. You also called it the IHC test. It states the abundance of her2 proteins in the cancer cells. The test results can show both 0 and 1+ negative status and 3+ positive or 2+ parameters and borderlines. The test results can be both positive and negative proving its presence or absence of the concerned HER2 gene amplification. What follows suit: Breast cancers with the primary amplification of this gene or protein over-expression pave the road for being HER2 positive when the pathology report gets out. Positive breast cancers are most likely to grow faster. They are more akin to spread all across the body and return. It’s different when you compare the same with HER2 negative cancers. However, the medicines exclusively cater to HER2 positive breast cancers. The third and fourth trial: The third test is known as Subtraction probe technology, which falls under the ambit of chromogenic in Situ hybridization. You also know it by the name of Spot Light or CISH Her2 test. The focus is on finding out the quantum of HER2 gene copies in the cancer cells. The last test is called Inform Dual, which is done in sync with SITU Hybridization. The tests find out the egregious load of HER2 copies in the cancer cells. Clinical trials show both negative and positive results for the main amplification. The net research: Modern research shows that some HER2 breast cancers have the knack of becoming HER2 negative in condition with time. It’s important to bear in mind is that if a breast cancer makes a comeback in the future as a more intricate disease; doctors must conduct a biopsy again to assess the HER2 status.